Viamet Pharmaceuticals, Inc.
Robert Schotzinger, Morrisville, NC, US
Viamet discovers and develops "best-in-class" small-molecule inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding, using their trade mark Metallophile Technology.
Dr. Lauren Silverman (Board Seat)